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PNL31
CLINICAL PRIOR AUTHORIZATION PROGRAM: A STRATEGY
FOR CONTROLLING DRUG EXPENDITURES AMONG
PATIENTS WITH INSOMNIA
Sun SX, McMurray J, Jacobsen V, Fuldeore M, Lee K, Bertram C
Walgreens Health Initiatives, Deerﬁeld, IL, USA
OBJECTIVE: Insomnia Clinical Prior Authorization (CPA)
program is designed to ensure appropriate utilization of insom-
nia medications and does not allow for chronic use unless
medical condition or medication is causing insomnia. The
purpose of this study was to evaluate the impact of the program
on the utilization and expenditures of insomnia medications.
METHODS: Using a retrospective pre-post with control group
study design, prescription records from January 1, 2003 to
October 31, 2004 were obtained from Walgreens Health Initia-
tives’ pharmacy claims database. The study group comprised of
166,719 eligible lives from three employer groups enrolled in 
the Insomnia CPA program, and the control group comprised 
of 501,779 eligible lives from 150 clients not enrolled in this
program. The number of prescriptions dispensed and the total
costs per member per month (PMPM) were analyzed for the two
groups in the pre and post period. PMPM cost savings (Y’) were
calculated using the following formula: Y¢ = Yst0*Rct - Yst1, where
Yst0 and Yst1 represent actual pre and post PMPM total costs in
the study group and Rct is the ratio of PMPM pre and post total
costs in the control group. RESULTS: From the pre to post
period, in the study group, the average number of prescriptions
per month increased by 8.5%, while the average PMPM costs
decreased by 8.4% (from $0.42 to $0.39). In the control group,
the average number of prescriptions per month as well as the
average PMPM costs increased by 63.3% and 42.9% respec-
tively. After comparing the trend among insomnia products in
these two groups, it was estimated that WHI’s Insomnia CPA
program resulted in $0.21 PMPM and total of $420,132 annu-
alized cost savings for the three employer groups. CONCLU-
SIONS: Clinical prior authorization program is effective in
controlling drug expenditures for patients with insomnia.
PNL32
PHYSICIAN AND PATIENT DETERMINANTS OF THE
TREATMENT OF SLEEP DIFFICULTIES IN OUTPATIENT
SETTINGS IN THE UNITED STATES
Rasu R1, Balkrishnan R2, Rajagopalan R3
1University of Texas Health Science Center, Houston,TX, USA;
2Ohio State University, Columbus, OH, USA; 3Takeda Pharmaceuticals
North America, Lincolnshire, IL, USA
OBJECTIVE: This study analyzed socioeconomic and clinical
factors relating to both physicians and patients associated with
physicians’ choice of the treatment for sleep difﬁculties in a
nationally representative sample of outpatient physician visits in
the US. METHODS: A modiﬁed version of the model suggested
by Eisenberg was used as a theoretical framework for this study
to predict the factors inﬂuencing treatment of sleep difﬁculties.
A multivariate logistic regression method was used to analyze
the 1996–2001 National Ambulatory Medical Care Survey data
to examine physician and patient related predictors of treatment
variations for sleep difﬁculties RESULTS: From 1996 to 2001,
about 4.8 billion visits were made to outpatient physician ofﬁces
in the US, and 94.6 million of these were sleep-difﬁculty related
visits. This study found that 32% of patients with sleep difﬁcul-
ties received no type of therapy during their visits and 5% of the
patients received behavioral therapy only. Psychiatrist visits were
72% more likely (OR: 1.72, 95% CI: 1.08–2.61) to be associ-
ated with receipt of medication therapy and ten times more likely
(OR: 10.19, 95% CI: 4.85–14.44) to be associated with behav-
ioral therapy prescription only than visits to family practitioners
and internists. Patient visits with public insurance as a primary
payer source were more likely to be associated with benzodi-
azepine prescription among patients receiving at least some 
medication therapy (OR: 1.66, 95% CI: 1.13–2.45) than patient
visits with private insurance as a primary payer source. CON-
CLUSIONS: The results of this study indicate that several patient
and physician characteristics inﬂuence physician prescribing of
treatments for sleep difﬁculties. This study suggests a need to
develop better care management guidelines for sleep difﬁculties
and a wider coverage of behavioral therapy in the US. The study
also ﬁnds variations in quality of care and treatment for sleep
difﬁculties in outpatient settings in the US.
PNL33
SLEEP COMPLAINTS AND DIAGNOSES IN THE NATIONAL
AMBULATORY MEDICAL CARE SURVEY: 1997–2002
Tan LSM, Morlock R
Pifzer Inc, Ann Arbor, MI, USA
OBJECTIVES: Insomnia symptoms have been reported to
impact the lives of approximately 83 million people of the United
States general population. However, insomnia complaints are
often underreported and underdiagnosed. This study describes
patient characteristics of those who do and do not present with
insomnia complaints in the National Ambulatory Medical Care
Survey (NAMCS). METHODS: Data was obtained from the 6
years of NAMCS data (1997 through 2002). Descriptive analy-
ses were utilized to examine individuals who listed insomnia as
one of three possible reasons for their ofﬁce visit relative to those
who did not have an insomnia complaint. Patient level weights
were utilized to derive US national population estimates. Given
the complex stratiﬁed survey design, Rao Scott and Wald Chi-
square tests were used to assess statistically signiﬁcant differences
within groups. RESULTS: Patients reported an insomnia com-
plaint as the reason for their visit in only 0.6% of all visits. The
majority of these patients (64%) were treated by primary care
specialists. Across all age groups, approximately twice as many
women as men presented with a complaint of insomnia.
However, a greater percentage of males under the age of 18 years
presented with an insomnia complaint compared to females in
the same age category, 18.3% compared to 11.2%, respectively.
While primary organic diagnoses (55.4%) were the most
common, an insomnia diagnosis occurred in 10.4% of patients
and a diagnosis of depression/anxiety occurred in 27.1% of
patients who listed insomnia as a reason for their visit. CON-
CLUSION: At any point in time insomnia complaints are known
to impact a signiﬁcant portion of the US population, yet, in only
0.6% visits do patients list insomnia as a reason for their visit.
This study provides an important descriptive look at those who
do and do not present with a complaint of insomnia.
PNL34
SEDATIVE HYPNOTICS EMPLOYED TO TREAT PATIENTS WITH
AND WITHOUT INSOMNIA COMPLAINTS IN THE NATIONAL
AMBULATORY MEDICAL CARE SURVEY: 1997–2002
Tan LSM, Morlock R
Pifzer Inc, Ann Arbor, MI, USA
OBJECTIVES: Pharmaceutical treatments are available for
patients with a complaint of insomnia. These treatments often
vary by patient and physician characteristics. This study
describes the use of several medications commonly used to treat
sleep disorders as reported in the National Ambulatory Medical
Care Survey (NAMCS). METHODS: Data was obtained from
the six years of NAMCS data (1997 through 2002). Analyses
were utilized to examine medications (ie., triazolam, temazepam,
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ﬂurazepam, zolpidem or zaleplon, trazadone, and diphenhy-
dramine) commonly used to treat individuals with a complaint
of insomnia. Patient level weights were utilized to derive US
national population estimates. Given the complex stratiﬁed
survey design, Rao Scott and Wald Chi-square tests were used
to assess statistically signiﬁcant differences within groups.
RESULTS: For all patients taking a medication commonly used
to treat sleep complaints, psychiatrists were more likely to pre-
scribe trazadone (54%), while family/general practice physicians
(29%), general internists (35%) and other specialists (28) were
more likely to prescribe zolpidem or zaleplon. Those 65 years
and older were more likely to be prescribed zolpidem or zale-
plon (30%) and younger patients were most often prescribed
trazadone (70%). CONCLUSION: Newer sleep agents such as
zolpidem or zaleplon are the most commonly prescribed med-
ication across the majority of physician-types. This study pro-
vides an important descriptive look at those who are taking
medications commonly used to treat sleep disorders.
PNL35
USING PATIENT REPORTED OUTCOMES (PROS) TO
DETERMINE THE PREVALENCE OF INSOMNIA IN 
FOUR COUNTRIES
Edmondson M,Annunziata K
Consumer Health Sciences, Princeton, NJ, USA
OBJECTIVE: To utilize international patient reported outcomes
(PROs) data and identify the size and impact of patient popula-
tions suffering from insomnia/sleep difﬁculty in four countries:
United States, UK, France, and Germany. METHODS: An
annual, self-reported study of consumer attitudes and behaviors
conducted by Consumer Health Sciences was ﬁelded in June,
2004 and completed by 60,050 adults, 18 years of age or older
in the United States (40,736), UK (8393), France (9011), and
Germany (9064). We stratiﬁed and weighted the sample by key
demographics. All respondents were asked if they experienced
insomnia or sleep difﬁculty within the past 12-months and if they
had their condition physician diagnosed. Respondents also com-
pleted the SF-8 and the WPAI. RESULTS: Of the 374.0 million
adults in the four countries examined, 27% (101.8 million)
reported to have experienced insomnia/sleep difﬁculty in the pre-
vious 12-months. The number of insomnia/sleep difﬁculty suf-
ferers in the United States is 53.2 million, 51% of total number
of sufferers, while the number of insomnia/sleep difﬁcult suffer-
ers in the UK, France and Germany combined is 48.6 million
adults, 49% of total number of sufferers. Diagnosed insom-
nia/sleep difﬁculty sufferers in the UK have the lowest SF-8
Mental health score: 39.2 and the lowest SF-8 Physical health
score: 37.9 (p < 0.05). The percentage of insomnia/sleep difﬁ-
culty sufferers who missed work due to their health 26% or 
more of the time was highest in France: 25.5% and lowest 
in the United States: 12.7% (p < 0.05). CONCLUSIONS: 
Insomnia/sleep difﬁculty remains a signiﬁcant health care issue
for adults in the United States, UK, France and Germany. The
impact that insomnia/sleep difﬁculty has on the quality of life
and productivity of adults warrants further investigation for
public policy makers and health care ofﬁcials.
RESPIRATORY DISORDERS
PRS1
PULMONOLOGISTS’ PERCEPTIONS OF ANEMIA IN COPD:
A SURVEY
Zilberberg M1, Pisano M2
1Ortho Biotech Clinical Affairs, LLC, Goshen, MA, USA; 2Ortho
Biotech Products, LP, Bridgewater, NJ, USA
OBJECTIVE: To understand the hemoglobin (Hb) thresholds
Pulmonologists (PULs) use to assess anemia severity in COPD.
METHODS: A survey was conducted to identify Hb thresholds
representing presence and severity of anemia in COPD.
RESULTS: One hundred PULs completed the survey at a spe-
cialty society meeting in 2004. All were either board-certiﬁed or
eligible in Pulmonary Medicine. Forty-seven percent have been
in practice for <5 years, with 30% and 23% in practice for 5–15
years and >15 years, respectively. The vast majority (86%) see
almost exclusively adult patients, 41% of the responders follow
<250 patients, while 41% see 250–1000 and 12% see >1000
patients with lung disease. Responders estimated that COPD
accounts for 49% of their lung disease patients, followed by
asthma (24%), lung cancer (13%) and obstructive sleep apnea
(13%). Only 21% of the PULs considered anemia to be Hb £
12g/dL. Furthermore, 37% of the responders considered Hb £
10g/dL to represent only mild anemia. Hb £ 9g/dL was identi-
ﬁed by 47% to represent moderate anemia, while Hb £ 8g/dL
was deemed to represent severe anemia by 75% of the respon-
ders. CONCLUSIONS: Despite the accepted WHO deﬁnition of
anemia (men, Hb < 13g/dL; women, Hb < 12g/dL), the major-
ity of PULs surveyed do not consider anemia to be present in
COPD patients until the Hb is <11g/dL, and a substantial
number consider a Hb < 10g/dL as only mild anemia. Results of
this survey suggest that PULs may not recognize mild anemia
which could lead to severe anemia and other complications.
PRS2
AN ASSESSMENT OF DIAGNOSIS AND TREATMENT OF 
COPD IN PRIMARY CARE VIA AN ELECTRONIC MEDICAL
RECORD DATABASE
Joish V1, Stockdale B1, Brady E1, Dirani R2, Brixner D1
1University of Utah, Salt Lake City, UT, USA; 2Pﬁzer Inc, New York, NY,
USA
The characteristics of Chronic Obstructive Pulmonary Disease
(COPD) patients and the patterns of treatment have not been
well characterized in primary care settings. Determining how
drug treatment patterns align with COPD diagnosis and sever-
ity may help optimize care. OBJECTIVE: This study was
designed to explore treatment patterns at the time of and post
COPD diagnosis. METHODS: A national electronic medical
record database was queried to identify patients with at least six-
months history prior to a diagnosis of COPD (ICD-9 codes
491.xx, 492.xx, and 496). Pulmonary function test (PFT) results
closest to the ﬁrst diagnosis of COPD were evaluated to charac-
terize disease severity using the Global Initiative for Chronic
Obstructive Lung Disease (GOLD) criteria. Prescription data
were evaluated at the time of diagnosis. All descriptive statistics
were conducted using STATA statistical software. RESULTS: A
total of 14,691 patients had COPD and six-months of data. Pre-
scription data at diagnosis were available for 9334 (64%) of
these patients. Of these, over 50% (n = 5264) had a prescription
on the date of diagnosis. The average number of days between
diagnosis and the ﬁrst prescription was 106 (SD+256.4). The
beta-adrenergic class was the most commonly prescribed therapy
(64%) post diagnosis. Only 273 (2%) of the 14,691 COPD
patients had PFT data adequate to determine the GOLD sever-
ity class. For this group, the average time from diagnosis to ﬁrst
prescription was inversely related to severity: 163 (SD+288.2)
days for Stage one and 124 (SD+152.3) days for Stage four.
CONCLUSIONS: COPD is often not diagnosed or treated until
the later stages of the disease, nor is PFT used routinely to diag-
nose, stage or guide treatment decisions. COPD severity seems
to inﬂuence the time between the date of diagnosis and physi-
cian prescription order.
